Related Experiment Video
Updated: Jun 20, 2026

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
How Would You Manage This Patient With Clostridioides difficile Infection? : Grand Rounds Discussion From Beth Israel
Zahir Kanjee1, Jessica R Allegretti2, Carolyn D Alonso3
1Division of General Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (Z.K., R.B.B.).
Insights
Updated guidelines for Clostridioides difficile infection management offer differing advice on antibiotic treatments for nonsevere disease and fecal microbiota transplantation for severe cases. Experts discuss these key differences in clinical practice.
Area of Science:
- Infectious Diseases
- Gastroenterology
- Clinical Practice Guidelines
Background:
- The Infectious Diseases Society of America/Society for Healthcare Epidemiology of America and the American College of Gastroenterology have issued new guidelines for managing Clostridioides difficile infection.
- These guidelines present generally aligned recommendations but include notable divergences in clinical advice.
Observation:
- Two experts, an infectious diseases specialist and a gastroenterologist, engage in a discussion regarding the updated guidelines.
- The discussion centers on antibiotic choices for nonsevere C. difficile infection, the utility of fecal microbiota transplantation in fulminant disease, and the application of bezlotoxumab for preventing recurrence.
Findings:
- The experts analyze specific treatment strategies, including antibiotic options for nonsevere disease and the role of fecal microbiota transplantation for fulminant cases.
- The use of bezlotoxumab to prevent recurrent C. difficile infection is examined within a clinical case scenario.
Implications:
- Clinicians must navigate nuanced differences between major society guidelines for optimal patient care.
- Understanding these distinctions is crucial for effective management of Clostridioides difficile infection, particularly in severe and recurrent cases.
Abstract:
The Infectious Diseases Society of America/Society for Healthcare Epidemiology of America and the American College of Gastroenterology recently released updated guidelines on management of patients with Clostridioides difficile infection. Although these 2 guidelines generally agree, there are a few important differences in their advice to clinicians. In these rounds, 2 experts, an infectious diseases specialist and a gastroenterologist, discuss antibiotic treatment options for nonsevere disease, the role of fecal microbiota transplantation for fulminant disease, and the use of bezlotoxumab to prevent recurrence in the context of Ms. C, a 48-year-old woman with fulminant C difficile infection.
Related Concept Videos
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management

